ImCheck Therapeutics is driving innovation in immune system modulation based on our unique know-how in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. We are designing the next generation of immunotherapeutic antibodies for the treatment of cancer, infectious disease, and autoimmune disease.
Latest news
ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023
Science & Medicine
Read more ImCheck To Present EVICTION-2 Data on ICT01 Combination With Low Dose IL-2 In Patients with Advanced Solid Tumors at SITC Annual Meeting
Science & Medicine
Read more ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023
Science & Medicine
Read more STAY IN TOUCH WITH OUR LATEST NEWS
Subscribe to receive our press releases and related news